Medical Device News Magazine

WIDEX Pure Sound Technology: New New Breakthrough Technology Reproduces Natural Sound in Hearing Aids

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

February 2, 2021

Widex PureSound technology, available for the first time in its new flagship WIDEX MOMENT™ hearing aids, features two distinct signal processing pathways — a “classic” version and a new ZeroDelay™ Accelerator pathway that dramatically changes how hearing aids sound.

“Sound quality and the ‘naturalness’ of sound remain among the most-cited reasons people don’t pursue hearing assistance, despite the great strides in hearing aid innovation made over the last decades,” said Widex Head of Audiology Lise Henningsen. “When hearing aids went digital, drastic improvements in noise reduction and advanced signal processing came at a price, but Widex has figured out how to overcome it.”

Taking an analog sound wave, converting it to a digital signal, processing it, then re-converting into a sound wave takes anywhere from 4 to 8 milliseconds. Studies have shown that a processing delay of that length can adversely affect sound quality, especially if processed sound and unprocessed sound mix in the ear canal of a hearing aid user, creating what is called a comb filter effect.

“When that happens, the perceived quality of the user’s own voice becomes tinny and artificial,” Henningsen said. “Environmental sounds come out distorted and unusual and, overall, the resulting sound becomes strenuous to listen to over time.”

The new Widex ZeroDelay Accelerator reduces the processing delay in WIDEX MOMENT hearing aids to below 0.5 milliseconds — a remarkable technological feat considering Widex already leads the industry with the lowest system delay through its “classic” processing pathway. The company’s unique, legacy time domain filter bank, 32kHz sampling rate, and 16kHz digital bandwidth create very high-fidelity sound across its family of hearing aids, with a processing delay under 3 milliseconds.

For the second, accelerated pathway in Widex PureSound-based hearing aids, signal processing is adapted to the ZeroDelay design to deliver the purest sound quality. Core functions, such as acoustics stability, adaptive gain control, and enhanced signal-to-noise ratio, continue to take priority, while others are modified for the faster ZeroDelay pathway. The two pathways — ZeroDelay and “classic” — exist side-by-side on the Widex PureSound platform. Depending on the needs of the wearer, a hearing care professional can program one or the other as the default mode. From there, the PureSound platform is adaptable to each user’s situation and preferred hearing experience.

“The wearer of hearing aids with the two distinct pathways can switch between them based on where they are and what they want to hear, thereby enjoying far greater sound quality and a more natural experience in most situations,” said Henningsen. Other information here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”